These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21833465)

  • 1. Differential effect of statins on diabetic nephropathy in db/db mice.
    Tamura Y; Murayama T; Minami M; Yokode M; Arai H
    Int J Mol Med; 2011 Nov; 28(5):683-7. PubMed ID: 21833465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ezetimibe ameliorates early diabetic nephropathy in db/db mice.
    Tamura Y; Murayama T; Minami M; Matsubara T; Yokode M; Arai H
    J Atheroscler Thromb; 2012; 19(7):608-18. PubMed ID: 22498767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy.
    Kimura S; Inoguchi T; Yokomizo H; Maeda Y; Sonoda N; Takayanagi R
    Diabetes Obes Metab; 2012 Jul; 14(7):666-9. PubMed ID: 22268518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice.
    Fujii M; Inoguchi T; Maeda Y; Sasaki S; Sawada F; Saito R; Kobayashi K; Sumimoto H; Takayanagi R
    Kidney Int; 2007 Aug; 72(4):473-80. PubMed ID: 17568784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.
    Giunti S; Calkin AC; Forbes JM; Allen TJ; Thomas MC; Cooper ME; Jandeleit-Dahm KA
    Am J Physiol Renal Physiol; 2010 Sep; 299(3):F528-35. PubMed ID: 20554645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy.
    Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
    J Atheroscler Thromb; 2011; 18(11):1018-28. PubMed ID: 21921413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
    Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
    Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin.
    Hu M; Tomlinson B
    Expert Opin Drug Metab Toxicol; 2014 Jan; 10(1):51-65. PubMed ID: 24156555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosuvastatin: new preparation. Opt for statins with evidence of efficacy on clinical outcome.
    Prescrire Int; 2004 Aug; 13(72):132-4. PubMed ID: 15532136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia.
    Takebayashi K; Suetsugu M; Matsumoto S; Aso Y; Inukai T
    South Med J; 2009 Apr; 102(4):361-8. PubMed ID: 19279518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes.
    Moriyama T; Oka K; Ueda H; Imai E
    Clin Exp Nephrol; 2004 Sep; 8(3):230-6. PubMed ID: 15480900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury.
    Whaley-Connell A; DeMarco VG; Lastra G; Manrique C; Nistala R; Cooper SA; Westerly B; Hayden MR; Wiedmeyer C; Wei Y; Sowers JR
    Am J Nephrol; 2008; 28(1):67-75. PubMed ID: 17914247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice.
    Jia ZH; Liu ZH; Zheng JM; Zeng CH; Li LS
    Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):571-6. PubMed ID: 17943690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients.
    Ogata N; Fujimori S; Oka Y; Kaneko K
    Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):321-4. PubMed ID: 20544514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of antioxidant defense mechanism by pitavastatin and rosuvastatin on obesity-induced oxidative stress in Wistar rats.
    Ansari JA; Bhandari U; Haque SE; Pillai KK
    Toxicol Mech Methods; 2012 Jan; 22(1):67-73. PubMed ID: 21859367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet.
    Fraulob JC; Souza-Mello V; Aguila MB; Mandarim-de-Lacerda CA
    Clin Sci (Lond); 2012 Aug; 123(4):259-70. PubMed ID: 22420611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
    Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
    Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.